JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells

Cancer Science

Volumn 101, Issue 3, 2010, Pages 774-781

  Tajima, Nobuyuki ^a   Fukui, Kenji ^a   Uesato, Naofumi ^a   Maruhashi, Junji ^a   Yoshida, Takayuki ^a   Watanabe, Yoshihiro ^a   Tojo, Arinobu ^b  

^a JAPAN TOBACCO INC   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; ETHYL N [3,5 DICHLORO 2 HYDROXY 4 [2 (4 METHYLPIPERAZIN 1 YL)ETHOXY]BENZOYL] LEVO PHENYLALANINATE; GROWTH FACTOR; JTE 607; MESSENGER RNA; MYC PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SURVIVAL TIME; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; PHENYLALANINE; PIPERAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949572880     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01446.x     Document Type: Article

References (50)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-62.
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-63.
3. Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005, 137-42.
4. Renneville A, Roumier C, Biggio V. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-31.
5. Tobler A, Moser B, Dewald B. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 1993, 82:2517-25.
6. Sugiyama H, Inoue K, Ogawa H. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma 1996, 21:49-52.
7. Hsu HC, Lee YM, Tsai WH. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 2002, 63:64-9.
8. Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud Ø. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res 2005, 29:185-96.
9. Padró T, Bieker R, Ruiz S. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002, 16:1302-10.
10. Hatfield K, Ryningen A, Corbascio M, Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006, 119:2313-21.
11. Kiss C, Benko I, Kovács P. Leukemic cells and the cytokine patchwork. Pediatr Blood Cancer 2004, 42:113-21.
12. Aguayo A, Kantarjian HM, Estey EH. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95:1923-30.
13. de Bont ES, Vellenga E, Molema G, van Wering E, de Leij LF, Kamps WA. A possible role for spontaneous interleukin-8 production by acute myeloid leukemic cells in angiogenesis related processes: work in progress. Med Pediatr Oncol 2001, 37:511-7.
14. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005, 5:229-48.
15. Aguayo A, Kantarjian H, Manshouri T. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-5.
16. Padró T, Ruiz S, Bieker R. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95:2637-44.
17. Kakutani M, Takeuchi K, Waga I, Iwamura H, Wakitani K. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res 1999, 48:461-8.
18. Iwamura H, Sato M, Wakitani K. Comparative study of glucocorticoids, cyclosporine A, and JTE-607[(-)-ethyl-N-{3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl}-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Ther 2004, 311:1256-63.
19. Sasaki J, Fujishima S, Iwamura H, Wakitani K, Aiso S, Aikawa N. Prior burn insult induces lethal acute lung injury in endotoxemic mice: effects of cytokine inhibition. Am J Physiol Lung Cell Mol Physiol 2003, 284:L270-8.
20. Uesato N, Fukui K, Maruhashi J, Tojo A, Tajima N. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol 2006, 34:1385-92.
21. Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986, 68:1178-81.
22. Murohashi I, Tohda S, Suzuki T, Nagata K, Yamashita Y, Nara N. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia. Blood 1989, 74:35-41.
23. Dunbar CE, Browder TM, Abrams JS, Nienhuis AW. COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science 1989, 245:1493-6.
24. Miyauchi J, Kelleher CA, Wong GG. The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture. Leukemia 1988, 2:382-7.
25. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L, Letendre F, Shaw A, Hoang T. Coordinate secretion of interleukin-1β and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as endogenous inducer. Blood 1990, 76:1481-9.
26. Murohashi I, Tohda S, Imai Y, Hirai Y, Nara N. Growth potentiating activity of endogenous production of interleukin-1 and tumor necrosis factor alpha in blast cells of acute myeloblastic leukemia. Exp Hematol 1993, 21:846-51.
27. Saily M, Koistinen P, Zheng A, Savolainen ER. Signaling through interleukin-6 receptor supports blast cell proliferation in acute myeloblastic leukemia. Eur J Haematol 1998, 61:190-6.
28. Asou H, Suzukawa K, Kita K. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn J Cancer Res 1996, 87:269-74.
29. Milella M, Precupanu CM, Gregorj C. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005, 11:2779-95.
30. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-12.
31. Coller HA, Grandori C, Tamayo P. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000, 97:3260-5.
32. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 2002, 21:3414-21.
33. Seoane J, Le H, Massagué J. Myc suppression of the p21Cip1 cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-34.
34. Wu S, Cetinkaya C, Munoz-Alonso MJ. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003, 22:351-60.
35. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-49.
36. Wu Q, Kirschmeier P, Hockenberry T. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 2002, 277:36329-37.
37. Liu S, Bishop WR, Liu M. Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003, 6:183-95.
38. Wang Z, Wang S, Fisher PB, Dent P, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation 2000, 66:1-13.
39. Radosevic N, Delmer A, Tang R, Marie JP, Ajchenbaum-Cymbalista F. Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure. Leukemia 2001, 15:559-66.
40. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 2003, 63:3637-45.
41. Freemerman AJ, Vrana JA, Tombes RM. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia 1997, 11:504-13.
42. Wang Z, Tuyle GV, Conrad D, Fisher PB, Dent P, Grant S. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res 1999, 59:1259-67.
43. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004, 5:793-804.
44. Kan Q, Jinno S, Kobayashi K, Yamamoto H, Okayama H. Cdc6 determines utilization of p21WAF1/CIP1-dependent damage checkpoint in S phase cells. J Biol Chem 2008, 283:17864-72.
45. Gottifredi V, McKinney K, Poyurovsky MV, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem 2004, 279:5802-10.
46. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997, 17:4877-82.
47. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006, 25:6731-48.
48. Negaard HF, Iversen N, Bowitz-Lothe IM. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009, 23:162-9.
49. Weigiel B, Ekberg J, Talasila KM, Jalili S, Persson JL. The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia 2009, 23:251-61.
50. Dias S, Hattori K, Heissig B. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 2001, 98:10857-62.